FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912983849> ?p ?o ?g. }

• W2912983849 endingPage "3130" @default.
• W2912983849 startingPage "3130" @default.
• W2912983849 abstract "Abstract Introduction: CD4+ T lymphocytes play a fundamental role in the adaptive immune system and traditionally their principle function has been seen as one of a 'helper' cell, interacting with and activating fellow immune cells to orchestrate and regulate the degree of immune response. There is a subset of CD4+T lymphocytes, however, that have the ability to acquire a cytotoxic phenotype. These cytotoxic CD4+ cells have been shown to have anti-viral functions but also they have previously been reported to exhibit anti-tumour effects in murine models of solid organ malignancies e.g. melanoma. The aim of this research was to identify, quantify and characterise cytotoxic CD4+ cells (CD4+ CTLs) in patients with Chronic Lymphocytic Leukaemia (CLL), to examine their association with cytomegalovirus (CMV) and to investigate the phenotype differences of the CD4+ CTLs isolated from patients who were CMV seropositive and seronegative. Methods: The peripheral blood (PB) from 90 patients with stable CLL (that was not requiring therapy) was collected after ethical approval and consent had been obtained. Flow cytometry was performed to identify and quantify the level of cytotoxic CD4+ cells (as defined as CD4+ Granzyme B+ cells) and to characterise the extended immunophenotype of the cells including transcription factors (including GATA-3, FoxP3, Eomes and Tbet) and co-inhibitory and co-stimulatory molecules (including LAG-3, TIM3, CTLA-4, PD-1, ICOS, OX40 and 4-1BB). In a subset of patients, serial samples of PB were collected to assess whether the quantity of cytotoxic CD4 cells changed over time in untreated CLL patients. Mass cytometry was performed to detect a broad range of surface molecules and to compare the extended phenotype of CD4+ (including CD4+ CTLs) and CD8+ cells in patients who were CMV seropositive and CMV seronegative in 14 patients with untreated CLL. An analysis of the CLL tumour environment was performed using multi-colour immunohistochemistry to detect CD4+ CTLs in paired bone marrow trephine and lymph node biopsies from a subset of patients. The expression of co-inhibitory and co-stimulatory molecules on the CD4+ CTLs was also examined in the bone marrow and lymph node biopsies. Results: The median age of the patients was 67 years (range: 41-90 years) with 29 females and 61 males. Fourteen patients had previously required treatment for CLL but were not currently on treatment and 76 patients had never required treatment. There was a significant increase in the percentage of CD4+ CTLs in the PB of those patients who were CMV seropositive when compared to those who were CMV seronegative (P<0.0001). Forty-five patients had PB samples collected at two different time-points and the median time between the two samples was 189 days (range: 7-735 days). The median difference in CD4+CTL values between the 2 samples for this group of patients was 0.19% (range: -25 - 46%). The extended immunophenotyping of the CD4+ CTLs showed that they had a phenotype more similar to cytotoxic CD8+ cells than non-cytotoxic CD4+ cells, with respect to both their transcription factor and checkpoint molecule expression. The mass cytometry analysis showed that there were significant differences in the expression of surface markers on CD4+ CTLs present in the PB of patients who were CMV seropositive compared with those who were CMV seronegative. The CD4+ CTLs were identified in both the bone marrow and lymph node biopsies. There was a significantly higher percentage of CD4+CTLs in the bone marrow trephine biopsies than in the lymph node biopsies (P=0.0068). Conclusions: This research identifies the presence of CD4+ CTLs in the PB, bone marrow and lymph node biopsies of patients with CLL. The transcription factor profile of CD4+ CTLs was more similar to cytotoxic CD8+ cells than non-cytotoxic CD4+ cells. Although a significantly higher percentage of CD4+CTLs was identified in patients who were CMV seropositive, CMV seronegative patients still retained a measurable population of CD4+ CTLs. The CD4+ CTLs in patients who were CMV seronegative had phenotypic differences when compared with CD4+ CTLs isolated from CMV seropositive patients, which may indicate an alternative, non-anti-viral function. Further research is required to explore whether the alternative function of CD4+ CTLs in CLL is an anti-tumour effect and to investigate the potential to harness them for therapeutic benefit in anti-tumour immunotherapies. Disclosures Nathwani: Freeline: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; BioMarin: Consultancy, Patents & Royalties; UniQure: Patents & Royalties." @default.
• W2912983849 created "2019-02-21" @default.
• W2912983849 creator A5001737873 @default.
• W2912983849 creator A5001865369 @default.
• W2912983849 creator A5012617779 @default.
• W2912983849 creator A5032635874 @default.
• W2912983849 creator A5045437232 @default.
• W2912983849 creator A5060666271 @default.
• W2912983849 creator A5067431043 @default.
• W2912983849 creator A5073895943 @default.
• W2912983849 creator A5077660148 @default.
• W2912983849 date "2018-11-29" @default.
• W2912983849 modified "2023-10-01" @default.
• W2912983849 title "Cytotoxic CD4+ Cells in Chronic Lymphocytic Leukaemia: An Extended Immunophenotypic Analysis Examining Their Association with Cytomegalovirus Serostatus and Similarities with Cytotoxic CD8+ Cells" @default.
• W2912983849 doi "https://doi.org/10.1182/blood-2018-99-116798" @default.
• W2912983849 hasPublicationYear "2018" @default.
• W2912983849 type Work @default.
• W2912983849 sameAs 2912983849 @default.
• W2912983849 citedByCount "0" @default.
• W2912983849 crossrefType "journal-article" @default.
• W2912983849 hasAuthorship W2912983849A5001737873 @default.
• W2912983849 hasAuthorship W2912983849A5001865369 @default.
• W2912983849 hasAuthorship W2912983849A5012617779 @default.
• W2912983849 hasAuthorship W2912983849A5032635874 @default.
• W2912983849 hasAuthorship W2912983849A5045437232 @default.
• W2912983849 hasAuthorship W2912983849A5060666271 @default.
• W2912983849 hasAuthorship W2912983849A5067431043 @default.
• W2912983849 hasAuthorship W2912983849A5073895943 @default.
• W2912983849 hasAuthorship W2912983849A5077660148 @default.
• W2912983849 hasBestOaLocation W29129838491 @default.
• W2912983849 hasConcept C154317977 @default.
• W2912983849 hasConcept C167672396 @default.
• W2912983849 hasConcept C183193105 @default.
• W2912983849 hasConcept C196166836 @default.
• W2912983849 hasConcept C202751555 @default.
• W2912983849 hasConcept C203014093 @default.
• W2912983849 hasConcept C2776062744 @default.
• W2912983849 hasConcept C2779727006 @default.
• W2912983849 hasConcept C2780380082 @default.
• W2912983849 hasConcept C54355233 @default.
• W2912983849 hasConcept C553184892 @default.
• W2912983849 hasConcept C86803240 @default.
• W2912983849 hasConcept C8891405 @default.
• W2912983849 hasConceptScore W2912983849C154317977 @default.
• W2912983849 hasConceptScore W2912983849C167672396 @default.
• W2912983849 hasConceptScore W2912983849C183193105 @default.
• W2912983849 hasConceptScore W2912983849C196166836 @default.
• W2912983849 hasConceptScore W2912983849C202751555 @default.
• W2912983849 hasConceptScore W2912983849C203014093 @default.
• W2912983849 hasConceptScore W2912983849C2776062744 @default.
• W2912983849 hasConceptScore W2912983849C2779727006 @default.
• W2912983849 hasConceptScore W2912983849C2780380082 @default.
• W2912983849 hasConceptScore W2912983849C54355233 @default.
• W2912983849 hasConceptScore W2912983849C553184892 @default.
• W2912983849 hasConceptScore W2912983849C86803240 @default.
• W2912983849 hasConceptScore W2912983849C8891405 @default.
• W2912983849 hasIssue "Supplement 1" @default.
• W2912983849 hasLocation W29129838491 @default.
• W2912983849 hasLocation W29129838492 @default.
• W2912983849 hasLocation W29129838493 @default.
• W2912983849 hasOpenAccess W2912983849 @default.
• W2912983849 hasPrimaryLocation W29129838491 @default.
• W2912983849 hasRelatedWork W1601672058 @default.
• W2912983849 hasRelatedWork W1993307935 @default.
• W2912983849 hasRelatedWork W2058581379 @default.
• W2912983849 hasRelatedWork W2111877332 @default.
• W2912983849 hasRelatedWork W2154219460 @default.
• W2912983849 hasRelatedWork W3205830276 @default.
• W2912983849 hasRelatedWork W3214820661 @default.
• W2912983849 hasRelatedWork W4200313168 @default.
• W2912983849 hasRelatedWork W4286560817 @default.
• W2912983849 hasRelatedWork W925785039 @default.
• W2912983849 hasVolume "132" @default.
• W2912983849 isParatext "false" @default.
• W2912983849 isRetracted "false" @default.
• W2912983849 magId "2912983849" @default.
• W2912983849 workType "article" @default.